Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Twist Bioscience Corporation, BeOne Medicines AG or BeOne Medicines AG because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Twist Bioscience Corporation, BeOne Medicines AG and BeOne Medicines AG compare based on key financial metrics to determine which better meets your investment needs.

About Twist Bioscience Corporation, BeOne Medicines AG and BeOne Medicines AG

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

Latest Biotechnology and Twist Bioscience Corporation, BeOne Medicines AG Stock News

As of October 27, 2026, Twist Bioscience Corporation had a $10.0 billion market capitalization, compared to the Biotechnology median of $227.8 million. Twist Bioscience Corporation’s stock is NA in 2026, NA in the previous five trading days and up 368.63% in the past year.

Currently, Twist Bioscience Corporation does not have a price-earnings ratio. Twist Bioscience Corporation’s trailing 12-month revenue is $431.8 million with a -31.7% net profit margin. Year-over-year quarterly sales growth most recently was 23.2%. Analysts expect adjusted earnings to reach $-1.196 per share for the current fiscal year. Twist Bioscience Corporation does not currently pay a dividend.

Currently, BeOne Medicines AG’s price-earnings ratio is 65.5. BeOne Medicines AG’s trailing 12-month revenue is $6.1 billion with a 10.7% net profit margin. Year-over-year quarterly sales growth most recently was 29.6%. Analysts expect adjusted earnings to reach $7.640 per share for the current fiscal year. BeOne Medicines AG does not currently pay a dividend.

How We Compare Twist Bioscience Corporation, BeOne Medicines AG and BeOne Medicines AG Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Twist Bioscience Corporation, BeOne Medicines AG and BeOne Medicines AG’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Twist Bioscience Corporation, BeOne Medicines AG and BeOne Medicines AG Stock Value Grades

Company	Ticker	Value
Twist Bioscience Corporation	TWST	F
BeOne Medicines AG	ONC	F
BeOne Medicines AG	ONC	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Twist Bioscience Corporation has a Value Score of 3, which is Ultra Expensive. BeOne Medicines AG has a Value Score of 7, which is Ultra Expensive. BeOne Medicines AG has a Value Score of 7, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Twist Bioscience Corporation, BeOne Medicines AG or BeOne Medicines AG has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Twist Bioscience Corporation, BeOne Medicines AG or BeOne Medicines AG is the better investment when it comes to value.

Twist Bioscience Corporation, BeOne Medicines AG and BeOne Medicines AG’s Momentum Grades

Company	Ticker	Momentum
Twist Bioscience Corporation	TWST	A
BeOne Medicines AG	ONC	B
BeOne Medicines AG	ONC	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Twist Bioscience Corporation has a Momentum Score of 99, which is Very Strong. BeOne Medicines AG has a Momentum Score of 71, which is Strong. BeOne Medicines AG has a Momentum Score of 71, which is Strong.

The Momentum Grade Winner: Twist Bioscience Corporation

As you can clearly see from the Momentum Grade breakdown above, Twist Bioscience Corporation is considered to have stronger momentum compared to BeOne Medicines AG. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Twist Bioscience Corporation could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Twist Bioscience Corporation, BeOne Medicines AG and BeOne Medicines AG’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Twist Bioscience Corporation	TWST	F
BeOne Medicines AG	ONC	B
BeOne Medicines AG	ONC	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Twist Bioscience Corporation has a Earnings Estimate Score of 18, which is Very Negative. BeOne Medicines AG has a Earnings Estimate Score of 73, which is Positive. BeOne Medicines AG has a Earnings Estimate Score of 73, which is Positive.

The Earnings Estimate Revisions Grade Winner: BeOne Medicines AG

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, BeOne Medicines AG has a better Earnings Estimate Revisions Grade than Twist Bioscience Corporation. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, BeOne Medicines AG could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Twist Bioscience Corporation, BeOne Medicines AG and BeOne Medicines AG Grades

In addition to Value, Estimate Revisions and Momentum, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Twist Bioscience Corporation, BeOne Medicines AG and BeOne Medicines AG pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Twist Bioscience Corporation, BeOne Medicines AG or BeOne Medicines AG Stock?

Overall, Twist Bioscience Corporation stock has a Value Score of 3, Momentum Score of 99 and Estimate Revisions Score of 18.

BeOne Medicines AG stock has a Value Score of 7, Momentum Score of 71 and Estimate Revisions Score of 73.

BeOne Medicines AG stock has a Value Score of 7, Momentum Score of 71 and Estimate Revisions Score of 73.

Comparing Twist Bioscience Corporation, BeOne Medicines AG and BeOne Medicines AG’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.